Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 5.

Journal Article

Mulder, Frits I., Candeloro, Matteo, Kamphuisen, Pieter W., Di Nisio, Marcello, Bossuyt, Patrick M., Guman, Noori, Smit, Kirsten, Buller, Harry R., van Es, Nick, Abdel-Razeq, H., Ades, S., Ayappan, S. R., Borchmann, S., Cella, C. A., Fankhauser, C. D., Ferroni, P., Fuentes, H. E., Kruger, S., Lim, S. H., Lubberts, S., Lustig, D. B., Mansfield, A. S., Munoz Martin, A. J., Noble, S., Panizo, E., Papaxoinis, G., Park, K., Patel, J. N., Posch, F., Ramos, J. D., Roselli, M., Santi, R., Sohal, D., Srikanthan, A., Tafur, A. J., Terbuch, A., Thomas, M., Vathiotis, O., Wang, R. and Zahir, M. N. (2019). The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica, 104 (6). S. 1277 - 1288. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Vansteenkiste, J. F., Smit, E. F., Groen, H. J. M., Garon, E. B., Heist, R. S., Hida, T., Nishio, M., Kokowski, K., Grohe, C., Reguart, N., Mansfield, A. S., Robeva, A., Ghebremariam, S., Waldron-Lynch, M., Akimov, M., Nwana, N., Giovannini, M. and Wolf, J. (2020). Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study. Ann. Oncol., 31. S. S830 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Wolf, J., Baik, C., Heist, R. S., Neal, J. W., Mansfield, A. S., Buettner, R., Davis, K. L., Giovannini, M., Mutebi, A. and Awad, M. M. (2018). Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts). Eur. J. Cancer, 103. S. E131 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Wolf, J., Groen, H. J. M., Akerley, W., Souquet, P. -J., Laack, E., Han, J. -Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Tan, D. S. W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M. and Orlov, S. (2020). Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. Oncol. Res. Treat., 43 (SUPPL 4). S. 143 - 144. BASEL: KARGER. ISSN 2296-5262

Wolf, J., Neal, J. W., Mansfield, A. S., Doban, V., Kanakamedala, H., Wu, W-H., Joshi, A., de Jong, E., Giovannini, M. and Baik, C. S. (2020). Comparison of clinical outcomes of patients with METDex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients. Ann. Oncol., 31. S. S863 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

This list was generated on Mon Oct 25 01:30:23 2021 CEST.